上 市 公 司 医药生物 ——HIV 治疗药物布局完善，长效预防引领新纪元 投资要点： 财务数据及盈利预测 | | 2024 | 2025Q1 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 418 | 198 | 806 | 998 | 1,263 | | 同比增长率（%） | 1.6 | 113.0 | 92.8 | 23.8 | 26.7 | | 归母净利润（百万元） | -141 | 16 | 7 | 89 | 166 | | 同比增长率（%） | - | - | - | 1,171.0 | 86.8 | | 每股收益（元/股） | -0.34 | 0.04 | 0.02 | 0.21 | 0.39 | | 毛利率（%） | 54.9 | 62.0 | 63.2 | 68.5 | 75.2 | | ROE（%） | -14.4 | 1.6 | 0.7 | 8.2 | 13.4 | | 市盈率 | -45 | | 908 | 71 | 38 | | 注： "净资产收益率"是指摊薄后归属于母公司所 ...

内容概要：HIV药物即抗艾滋病病毒的药物。艾滋病患者数量庞大，HIV药物发展空间广阔，截至2024 年末，全国31个省报告现存活艾滋病病毒（HIV）感染者/AIDS患者135.5万例。现存活HIV感染者74.98 例，AIDS患者60.52例。鉴于我国存活患者人数持续扩大、医保范围逐渐扩大、患病人群支付能力提升 等因素，我国抗HIV病毒药物发展迅速，市场规模大幅增长。2021-2024年中国HIV药物市场规模增速保 持在20%以上，2024年同比大幅增长30.2%达58.36亿元。我国实施"四免一关怀"政策，包括免费向农村 艾滋病病人和城镇经济困难的艾滋病病人提供抗艾滋病病毒治疗药品。2022年以前，免费药物一直是 HIV药物主要市场。随着居民收入持续增加，医疗支付能力不断提升及越来越多的创新HIV药纳入医 保，2022年自费药物市场规模超过免费药物，自费药物市场规模迅速扩大，2024年达37.87亿元，同比 增长47.5%，成为拉动HIV药增长的主要驱动力。2024年免费药物市场规模为20.49亿元，同比增长7%。 目前国内仍以抗HIV仿制药市场为主，截至2024年末，仅有4款国产创新药上市，分别为前沿生物 ...

Core Insights - The report emphasizes the flourishing approval of new drugs and highlights the importance of focusing on technological tracks and opportunities within the industry chain [1][5] - It suggests a dual growth strategy combining internal and external growth, particularly in the context of the imminent patent cliff for IO1.0 and the increasing recognition of Chinese innovative pharmaceutical companies globally [5] Industry Overview - The report notes a significant recovery in domestic healthcare policies, including the integration of commercial insurance into the medical insurance system and the inclusion of high-priced innovative drugs in the Class B medical insurance catalog [5] - The overall revenue growth rate for chemical pharmaceutical companies in 2024 is projected at 4.10%, a substantial increase from 0.24% in 2023, while the net profit growth rate is expected to be 51.66% [12][15] Investment Opportunities - Short-term focus is recommended on certain tracks with high certainty, such as IO+ADC, while long-term investments should target new technologies with significant potential, including small nucleic acids and CAR-T [5] - The report categorizes various technological tracks for investment, including combinations of PD-1 with other mechanisms and innovative solutions for unmet clinical needs [5] Company Valuations - The report provides a comparative valuation of unprofitable innovative pharmaceutical companies, highlighting their market capitalizations and projected revenues for 2024 to 2027 [6] - It also presents a comparative valuation of profitable innovative pharmaceutical companies, detailing their market capitalizations and projected net profits for the same period [8] Performance Review - The report reviews the performance of pharmaceutical companies in 2024 and Q1 2025, noting that while the overall industry faced temporary pressure, gross profit margins have steadily improved [12][15] - It highlights that many small and mid-cap innovative pharmaceutical companies have turned profitable in Q1 2025, indicating a positive trend in the sector [18]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-031 江苏艾迪药业股份有限公司 关于变更部分募集资金投资项目及金额调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 经中国证券监督管理委员会出具《关于同意江苏艾迪药业股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1185 号）核准，公司向社会 公开发行人民币普通股 6,000 万股，发行价为每股人民币 13.99 元，募集资金总 额 为 人 民 币 839,400,000.00 元 ， 扣 除 承 销 费 用 和 保 荐 费 用 合 计 含 税 金 额 生 发 行 费 用 含 税 人 民 币 79,833,781.03 元 ， 包 含 可 抵 扣 增 值 税 进 项 税 额 | | | | | 截至 | 2025 | 年 6 | 截至 2025 | 年 6 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 变更前募投项目名 | | 预计投资总 | ...